[ad_1]
Pharmaceutical conglomerate AstraZeneca expects to present the efficacy of the COVID-19 vaccine by the end of the year and is increasing production to supply hundreds of millions of doses starting in January.
Pharmaceutical conglomerate AstraZeneca expects to present the effectiveness of the COVID-19 vaccine by the end of the year and is increasing production to supply hundreds of millions of doses starting in January, it was announced today.
The information was advanced by executive director Pascal Soriot, quoted by Associated Press (AP). The conglomerate has an established protocol with the University of Oxford to develop one of the most anticipated vaccines, which is in the latest clinical trials in the United States of America (USA), United Kingdom and other countries, to determine its safety and effectiveness.
Once the results are presented, the different regulatory authorities must approve the vaccine for mass use.
“We align the delivery time of the vials with the reading time of the clinical trials,” Soriot explained at a press conference, adding that, globally, it will be possible to provide “hundreds of millions of doses of the vaccine.” as of January. .
Several governments and health authorities are eagerly awaiting the development of a vaccine as the most effective method to finally curb the spread of the pandemic disease (covid-19) caused by the new coronavirus (SARS-CoV-2), which has already caused death. to more than 1.2 million people around the world.
Both the conglomerate and the University of Oxford have pledged to distribute the vaccine at no cost for the duration of the pandemic. Once the pandemic is controlled, the vaccine will continue to be distributed in this way to developing countries, but more developed countries will have to buy the vaccine at a “relatively low” cost.
The head of the entity responsible for the analysis of vaccines in the United Kingdom, Cate Bingham, explained that there are two candidate vaccines – that of AstraZeneca and Oxford and that of Pfizer in collaboration with BioNTech – whose data should be available for consultation in December.
US and British regulators are working at a fast pace to allow for faster approval of the vaccine.
“If we succeed, we will have a chance to implement it by the end of the year,” Bingham explained during a parliamentary hearing on Wednesday.
The official revealed that there should be four million doses of the vaccine available to the UK by the end of 2020, but the government estimates to secure 30 million by September 2021.
The covid-19 pandemic has already claimed more than 1.2 million deaths in more than 48.1 million cases of infection worldwide, according to a report by the French agency AFP.
The disease is transmitted by a new coronavirus detected at the end of December 2019 in Wuhan, a city in central China.
[ad_2]
